Why You’re Losing Muscle on Weight Loss Drugs, and What a Gut Hormone Might Do About It

Every time you swallow something fatty, your small intestine quietly releases a hormone called FGF19. It travels to your liver, taps the brakes on bile acid production, and nudges the whole digestive apparatus toward equilibrium. A background signal, modest and chemical, doing its job without fanfare. Most people have never heard of it. Researchers at the University of Michigan now think it might be one of the most important variables in the entire weight loss equation.

Obesity affects roughly 40 percent of American adults, and the pharmaceutical response to that statistic has been, by any measure, dramatic. GLP-1 receptor agonists like semaglutide have generated the kind of clinical enthusiasm that borders on collective relief. The drugs work. Bodies get lighter. Blood sugar improves. But something else tends to happen too, something clinicians have been watching with quiet concern: lean mass goes with the fat.

The Muscle Problem Nobody Is Talking About

Lean mass, mostly skeletal muscle, is not simply the stuff that makes you look toned. It is metabolically active tissue; it burns calories at rest, it underpins physical function, and its loss is, to put it bluntly, one of the main reasons people regain weight after successful treatment. If you shed fat and muscle together during rapid weight loss, you come out the other side with a body that is smaller but in some ways metabolically worse off. The weight tends to come back. Usually as fat.

Bozadjieva-Kramer and her colleagues had been chasing a related question for years. Earlier work from the same group suggested FGF15 (the mouse equivalent of human FGF19) protects lean mass after sleeve gastrectomy. And a separate observation in humans hinted that baseline levels of FGF19 might predict how much muscle a person loses during a very-low-energy diet. Not every patient responded the same way. Some preserved muscle well. Others didn’t. “We were interested in understanding whether the levels of FGF15/19 could broadly predict weight loss outcomes,” said Nadejda Bozadjieva-Kramer, Assistant Professor of Surgery and member of the Caswell Diabetes Institute.

The new study, published in the journal Diabetes, tested that logic more rigorously than anything her team had done before. Two groups of mice, both fattened on high-fat diets for 22 weeks. Some had normal FGF15 function; others had been engineered to lack it entirely. Then the researchers split their approach. One set of animals simply had their diets switched back to standard chow. The other set stayed on the high-fat diet but started receiving daily semaglutide injections.

Two Routes Down the Same Mountain

What they found draws a line between two things that are often treated as equivalent: losing weight by eating less versus losing weight by drug. Diet was more effective at clearing fat from the liver and reducing overall body weight. Semaglutide, on the other hand, produced better improvement in glucose tolerance, that measure of how gracefully the body handles blood sugar. Different paths; different metabolic consequences.

But the muscle story was the one that complicated everything. Mice lacking FGF15 lost significantly more lean mass when their diet changed. The hormone, it seems, is doing something protective during dietary weight loss that goes beyond its known role in bile acid regulation. Without it, muscle erodes faster. With it, the body holds on.

Semaglutide was less discriminating. It decreased lean mass in all the animals, regardless of whether they had FGF15. The drug simply didn’t care. Which is, in a way, a useful finding: it tells you that the gut hormone pathway relevant to dietary lean mass preservation is not the same pathway semaglutide is using. These are not redundant mechanisms. They are probably complementary, and right now we are mostly triggering one while ignoring the other.

“Weight loss is not a one-size-fits-all approach, and the specific treatment approach matters,” Bozadjieva-Kramer said. “It involves complex communication between the gut and liver, and understanding weight loss can help us tailor specific weight loss interventions for our patients.”

The bile acid data added another layer. Semaglutide modulated the composition of bile acids in ways that were particularly pronounced in mice lacking FGF15, suggesting the hormone is also involved in buffering whatever shifts the drug produces in gut chemistry. Remove FGF15 and the system responds more dramatically, less stably. It is, perhaps, a hint at why some patients on GLP-1 drugs experience gut side effects more intensely than others.

Toward Combinations That Make More Sense

There are real limits to what this study can tell us. The researchers acknowledge that clinical weight loss is most effective when GLP-1 drugs are combined with diet and exercise, a combination this study did not examine. Mouse models have their own particular metabolism; lean mass in a rodent is not a perfect proxy for lean mass in a person carrying two jobs and three kids. The leap from knockout mice to a clinical decision is still a long one.

But the underlying question is already in the room. If FGF19 levels in the blood can predict, before treatment even starts, how well a patient will hold on to muscle during weight loss, that is clinically useful. It is the kind of biomarker that could, eventually, help a physician say: this patient would benefit from a dietary approach; that one would do better with semaglutide; perhaps this third patient needs a combination we have not yet optimised. The team is now working to understand how to combine dietary and pharmacological strategies to maximise metabolic benefits while minimising lean mass loss. The gut, it turns out, is not just digesting your food. It is negotiating your future.

DOI: 10.2337/db25-0466

Frequently Asked Questions

Why do weight loss drugs like semaglutide cause muscle loss?

Semaglutide reduces appetite and body weight, but the body doesn’t distinguish cleanly between fat and muscle when shedding mass rapidly. Skeletal muscle is metabolically costly to maintain, so the body tends to cannibalize it alongside fat stores during aggressive caloric restriction. The Michigan study found this happened regardless of whether the gut hormone FGF15 was present, suggesting semaglutide acts through a different biological pathway than the ones that normally protect muscle during dietary weight loss.

Does losing muscle during weight loss make it harder to keep the weight off?

Probably, yes. Skeletal muscle burns calories at rest, so losing it reduces your resting metabolic rate, meaning your body needs fewer calories to function. If you then return to your previous eating habits, or even a modest diet, you are more likely to regain weight as fat rather than muscle. This is one reason why preserving lean mass is increasingly seen as a central goal of obesity treatment, not a cosmetic afterthought.

Could measuring FGF19 levels before treatment help doctors choose the right approach?

That is the working hypothesis this research is building toward. Earlier work from the same Michigan group showed that baseline FGF19 levels in humans can predict how much lean mass a person loses during a very-low-energy diet. If that predictive relationship holds up in larger clinical studies, a simple blood test before starting a weight loss programme could in principle guide treatment choices, though significant validation work remains.

Is diet still better than semaglutide for weight loss?

The study found that switching back to a standard diet was more effective at reducing liver fat and overall body weight, while semaglutide produced greater improvement in blood sugar control. Neither approach is straightforwardly better; they produce different metabolic outcomes and likely suit different patients. The real clinical question, which this study did not address, is how the two approaches work in combination with exercise, which remains the gold standard recommendation.